2018
Guanfacine treatment for prefrontal cognitive dysfunction in older participants: a randomized clinical trial
Barcelos NM, Van Ness PH, Wagner AF, MacAvoy MG, Mecca AP, Anderson GM, Trentalange M, Hawkins KA, Sano M, Arnsten AFT, van Dyck CH. Guanfacine treatment for prefrontal cognitive dysfunction in older participants: a randomized clinical trial. Neurobiology Of Aging 2018, 70: 117-124. PMID: 30007160, PMCID: PMC6503670, DOI: 10.1016/j.neurobiolaging.2018.05.033.Peer-Reviewed Original ResearchConceptsDose of guanfacineQuality of lifeZ-scoreCognitive functionPrefrontal cognitive dysfunctionCommon adverse eventsPrimary outcome measureRandomized clinical trialsGlobal functionOlder participantsHealthy older participantsPrefrontal cognitive functionDry mouthAdverse eventsAgonist guanfacineClinical trialsGuanfacine treatmentCognitive dysfunctionMean changeOutcome measuresPlaceboGuanfacineOlder individualsWeeksDose
2013
Transcranial Magnetic Stimulation of Wernicke’s and Right Homologous Sites to Curtail “Voices”: A Randomized Trial
Hoffman RE, Wu K, Pittman B, Cahill JD, Hawkins KA, Fernandez T, Hannestad J. Transcranial Magnetic Stimulation of Wernicke’s and Right Homologous Sites to Curtail “Voices”: A Randomized Trial. Biological Psychiatry 2013, 73: 1008-1014. PMID: 23485015, PMCID: PMC3641174, DOI: 10.1016/j.biopsych.2013.01.016.Peer-Reviewed Original Research
2012
Glycine treatment of the risk syndrome for psychosis: Report of two pilot studies
Woods SW, Walsh BC, Hawkins KA, Miller TJ, Saksa JR, D'Souza DC, Pearlson GD, Javitt DC, McGlashan TH, Krystal JH. Glycine treatment of the risk syndrome for psychosis: Report of two pilot studies. European Neuropsychopharmacology 2012, 23: 931-940. PMID: 23089076, PMCID: PMC4028140, DOI: 10.1016/j.euroneuro.2012.09.008.Peer-Reviewed Original ResearchConceptsPilot studyRisk syndromeSyndrome patientsNegative symptomsShort-term pilot studyEffect sizeAdjunctive antipsychotic medicationOpen-label studyPatients meeting criteriaNMDA receptor functionDurability of effectPsychosis risk symptomsGlycine site agonistsGroup effect sizesWeeks of evaluationAntipsychotic medicationSyndrome subjectsPromising effect sizesTreatment needsLarge effect sizesMeeting criteriaCognitive impairmentReduced symptomsReceptor functionSymptoms
2008
Neuropsychological course in the prodrome and first episode of psychosis: Findings from the PRIME North America Double Blind Treatment Study
Hawkins KA, Keefe RS, Christensen BK, Addington J, Woods SW, Callahan J, Zipursky RB, Perkins DO, Tohen M, Breier A, McGlashan TH. Neuropsychological course in the prodrome and first episode of psychosis: Findings from the PRIME North America Double Blind Treatment Study. Schizophrenia Research 2008, 105: 1-9. PMID: 18774696, DOI: 10.1016/j.schres.2008.07.008.Peer-Reviewed Original ResearchConceptsNeuropsychological courseDouble-blind treatment studyNeuropsychological StatusPlacebo-assigned subjectsPutative prodromal stateDouble-blind trialFrank psychotic episodeEarly convertersOlanzapine treatmentNeuropsychological deficienciesFrank psychosisMedication studiesFirst episodePsychotic episodeProdromal stateHigh riskBlind trialNeuropsychological declineTreatment studiesPsychotic conditionsPsychosisLate convertersOlanzapineProdromeInitial assessment
2006
Randomized, Double-Blind Trial of Olanzapine Versus Placebo in Patients Prodromally Symptomatic for Psychosis
McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller T, Woods SW, Hawkins KA, Hoffman RE, Preda A, Epstein I, Addington D, Lindborg S, Trzaskoma Q, Tohen M, Breier A. Randomized, Double-Blind Trial of Olanzapine Versus Placebo in Patients Prodromally Symptomatic for Psychosis. American Journal Of Psychiatry 2006, 163: 790-799. PMID: 16648318, DOI: 10.1176/ajp.2006.163.5.790.Peer-Reviewed Original ResearchConceptsOlanzapine patientsPlacebo patientsProdromal symptomsPsychosis ratesDouble-blind treatment periodEfficacy of olanzapineFurther treatment researchOlanzapine Versus PlaceboOlanzapine-treated patientsDouble-blind trialPhase of illnessPositive prodromal symptomsInduced Weight GainHazard of conversionSignificant differencesNorth American clinicsSignificant treatment differencesOlanzapine groupVersus PlaceboPlacebo groupSymptom scoresEfficacy measuresWeek 8Treatment periodPatients
2005
Temporoparietal Transcranial Magnetic Stimulation for Auditory Hallucinations: Safety, Efficacy and Moderators in a Fifty Patient Sample
Hoffman RE, Gueorguieva R, Hawkins KA, Varanko M, Boutros NN, Wu YT, Carroll K, Krystal JH. Temporoparietal Transcranial Magnetic Stimulation for Auditory Hallucinations: Safety, Efficacy and Moderators in a Fifty Patient Sample. Biological Psychiatry 2005, 58: 97-104. PMID: 15936729, DOI: 10.1016/j.biopsych.2005.03.041.Peer-Reviewed Original ResearchConceptsRepetitive transcranial magnetic stimulationTranscranial magnetic stimulationAuditory hallucinationsSham stimulationMagnetic stimulationTemporoparietal repetitive transcranial magnetic stimulationClinical Global Impression ScaleGlobal Impression ScaleRight-handed patientsMotor thresholdImpression ScaleRTMS effectsNew patientsNeurocognitive impairmentHallucination frequencySchizoaffective disorderPatient samplesSignificant distressPatientsChange scoresHallucinationsPreliminary reportStimulationNeurobiological factorsIntervention
2003
The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis I. Study rationale and design
McGlashan TH, Zipursky RB, Perkins D, Addington J, Miller TJ, Woods SW, Hawkins KA, Hoffman R, Lindborg S, Tohen M, Breier A. The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis I. Study rationale and design. Schizophrenia Research 2003, 61: 7-18. PMID: 12648731, DOI: 10.1016/s0920-9964(02)00439-5.Peer-Reviewed Original ResearchConceptsPsychosis onsetClinical trialsDouble-blind placebo-controlled clinical trialStudy rationaleDouble-blind clinical trialPlacebo-controlled clinical trialAtypical neuroleptic medicationsNew diagnostic criteriaClinical trial designPutative prodromal syndromeTreatment-seeking patientsOngoing symptomatologyNeuroleptic medicationHigh riskDiagnostic criteriaTrial designEarly courseProdromal SyndromesClinical phenomenologyStudy designClinical populationsPatientsOnsetIntervention researchTrialsThe PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis II. Baseline characteristics of the “prodromal” sample
Miller TJ, Zipursky RB, Perkins D, Addington J, Woods SW, Hawkins KA, Hoffman R, Preda A, Epstein I, Addington D, Lindborg S, Marquez E, Tohen M, Breier A, McGlashan TH. The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis II. Baseline characteristics of the “prodromal” sample. Schizophrenia Research 2003, 61: 19-30. PMID: 12648732, DOI: 10.1016/s0920-9964(02)00440-1.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAntipsychotic AgentsBenzodiazepinesBipolar DisorderComorbidityDepressive Disorder, MajorDouble-Blind MethodFemaleHumansMaleMood DisordersOlanzapinePirenzepinePsychomotor DisordersPsychotic DisordersRisk FactorsSchizophreniaSchizophrenic PsychologySleep Wake DisordersSpeech DisordersConceptsFirst-episode schizophreniaEpisode schizophreniaTreatment-seeking patientsClinical trialsDouble-blind placebo-controlled clinical trialProdromal SyndromesDouble-blind clinical trialPlacebo-controlled clinical trialAtypical neuroleptic medicationsMild affective symptomsNew diagnostic criteriaSerious mental illnessClinical trial samplesUntreated first-episode schizophreniaSubstance use/abuseEffects of drugsPutative prodromal syndromeUse/abuseUnusual thought contentAdolescent maniaOngoing symptomatologyProdromal sampleStudy medicationBaseline characteristicsMost patients